5-hydroxymethyldeoxycytidine monophosphate profile

5-hydroxymethyl-2'-deoxycytidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	169016
CHEMBL ID	597779
SCHEMBL ID	231959
MeSH ID	M0188111

Synonym
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-(hydroxymethyl)pyrimidin-2-one
4-amino-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-hydroxymethyl-1h-pyrimidin-2-one
5-hydroxymethyldeoxycytidine monophosphate
5-hydroxymethyl-2'-deoxycytidine
5-(hydroxymethyl)deoxycytidine
5-(hydroxymethyl)-2'-deoxycytidine
cytidine, 2'-deoxy-5-(hydroxymethyl)-
CHEMBL597779
7226-77-9
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)pyrimidin-2-one
hm-dcmp
SCHEMBL231959
AKOS022183455
5-hydroxymethyl-2??-deoxycytidine
J-700033
HMUOMFLFUUHUPE-XLPZGREQSA-N
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)-1,2-dihydropyrimidin-2-one
AS-65435
mfcd09842113
4-amino-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(hydroxymethyl)pyrimidin-2(1h)-one
1-(2-deoxypentofuranosyl)-5-(hydroxymethyl)-4-imino-1,4-dihydropyrimidin-2-ol
DTXSID50993019
D90265
5-hydroxymethyl-2 inverted exclamation mark -deoxycytidine
HY-131394
CS-0134009
PD017712

Assay ID	Title	Year	Journal	Article
AID458878	Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 4 serial passages with uninfected cells by serial passage experiment	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.
AID458876	Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.
AID458875	Cytotoxicity against human CEM-SS cells by MTT assay	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.
AID458874	Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.
AID458879	Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 4 to 8 serial passages with uninfected cells by serial passage experiment	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.
AID1714494	Displacement of sodium 5-(3-(8-(3-carboxy-N-hydroxyacrylamido)octyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoate from Naegleria Tet-1 at 5 mM incubated for 20 mins followed by sodium 5-(3-(8-(3-carboxy-N-hydroxyacrylamido)octyl)thioureido)-2-(6	2016	ACS medicinal chemistry letters, Feb-11, Volume: 7, Issue:2	A Fluorescence Polarization Biophysical Assay for the Naegleria DNA Hydroxylase Tet1.
AID458877	Cytotoxicity against human MT4 cells by MTT assay	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (3.85)	18.2507
2000's	1 (3.85)	29.6817
2010's	20 (76.92)	24.3611
2020's	4 (15.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
alpha-ketoglutaric acid 2-oxoglutaric acid : An oxo dicarboxylic acid that consists of glutaric acid bearing an oxo substituent at position 2. It is an intermediate metabolite in Krebs cycle.	2.13	1	oxo dicarboxylic acid	fundamental metabolite
malic acid malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.	2.17	1	2-hydroxydicarboxylic acid; C4-dicarboxylic acid	food acidity regulator; fundamental metabolite
cytosine [no description available]	3.19	5	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.13	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
phthalic acid phthalic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7178. phthalic acid : A benzenedicarboxylic acid cosisting of two carboxy groups at ortho positions.	2.13	1	benzenedicarboxylic acid	human xenobiotic metabolite
thymine [no description available]	2.15	1	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	2.17	1	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
thymidine [no description available]	3.42	6	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
uridine [no description available]	2.11	1	uridines	drug metabolite; fundamental metabolite; human metabolite
cytidine [no description available]	2.81	3	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pentoxyl Pentoxyl: 5-Hydroxymethyl-6-methyl- 2,4-(1H,3H)-pyrimidinedione. Uracil derivative used in combination with toxic antibiotics to lessen their toxicity; also to stimulate leukopoiesis and immunity. Synonyms: pentoksil; hydroxymethylmethyluracil.	2.1	1	pyrimidone
2,4-pyridinedicarboxylic acid lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.	2.13	1	pyridinedicarboxylic acid
deoxycytidine [no description available]	4.56	22	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyuridine [no description available]	2.06	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxycytidine monophosphate Deoxycytidine Monophosphate: Deoxycytidine (dihydrogen phosphate). A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions.. 2'-deoxycytosine 5'-monophosphate : A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having cytosine as the nucleobase.	2.43	2	2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; mouse metabolite
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.05	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
5-methylcytosine 5-Methylcytosine: A methylated nucleotide base found in eukaryotic DNA. In ANIMALS, the DNA METHYLATION of CYTOSINE to form 5-methylcytosine is found primarily in the palindromic sequence CpG. In PLANTS, the methylated sequence is CpNpGp, where N can be any base.. 5-methylcytosine : A pyrimidine that is a derivative of cytosine, having a methyl group at the 5-position.	3.82	10	methylcytosine; pyrimidines	human metabolite
metaperiodate Periodic Acid: A strong oxidizing agent.	2.13	1	iodine oxoacid
5-hydroxymethylcytosine 5-(hydroxymethyl)cytosine : A nucleobase analogue that is cytosine in which the hydrogen at position 5 is replaced by a hydroxymethyl group.	2.77	3	aminopyrimidine; aromatic primary alcohol; nucleobase analogue; pyrimidone	human metabolite; mouse metabolite
5-hydroxymethyluracil [no description available]	2.1	1	primary alcohol; pyrimidone	human metabolite
5-hydroxymethyl-2'-deoxyuridine [no description available]	2.05	1	pyrimidine 2'-deoxyribonucleoside
5-methylcytidine [no description available]	2.52	2	methylcytidine
5-hydroxy-2'-deoxyuridine 5-hydroxy-2'-deoxyuridine: a major oxidation product of 2'-deoxycytidine	2.05	1
metaperiodate metaperiodate: RN given refers to periodic acid, Na salt; structure. periodate : A monovalent inorganic anion obtained by deprotonation of periodic acid.	2.13	1	iodine oxoanion; monovalent inorganic anion
d-2-hydroxyglutarate (R)-2-hydroxyglutaric acid : The (R)-enantiomer of 2-hydroxyglutaric acid.	2.13	1	2-hydroxyglutaric acid	algal metabolite
5-methyldeoxycytidine [no description available]	3.37	6	2'-deoxycytidine
dimethyl fumarate [no description available]	2.17	1	diester; enoate ester; methyl ester	antipsoriatic; immunomodulator
oxalylglycine oxalylglycine: structure given in first source. N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes.	2.13	1	amino dicarboxylic acid; N-acylglycine	EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor
phosphoramidite phosphoramidite: structure in first source. phosphoramidite : A compound with the general formula (RO)2PNR2. Phosphoramidites can be regarded as phosphites that have an NR2 instead of an OH group, or as amides of phosphorous acid.	2.47	2
5-Hydroxymethylcytidine 5-hydroxymethylcytidine: an epigenetic modification marker of DNA and RNA	2.17	1	pyrimidine nucleoside
5-formyl-2'-deoxycytidine 5-formyl-2'-deoxycytidine: structure in first source	3.04	4
oligonucleotides [no description available]	2.06	1
olaparib [no description available]	2.31	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
5-hydroxymethyl-2'-deoxyuridine 5-hydroxymethyl-2'-deoxyuridine : A pyrimidine 2'-deoxyribonucleoside composed of 2'-deoxyuridine having a 5-hydroxymethyl substituent.	3.42	6

Condition	Relationship Strength	Studies
Genome Instability [description not available]	2.61	2
Anemia, Fanconi [description not available]	2.41	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.41	1
Carcinoma, Epidermoid [description not available]	2.17	1
MS (Multiple Sclerosis) [description not available]	2.17	1
Cancer of Skin [description not available]	2.17	1
Local Neoplasm Recurrence [description not available]	2.17	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.17	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.17	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.17	1
Benign Fibrous Mesothelioma [description not available]	2.21	1
Malignant Mesothelioma [description not available]	2.21	1
Cancer of Lung [description not available]	2.21	1
Neoplasms, Pleural [description not available]	2.21	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.21	1
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	2.21	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.21	1
Atherogenesis [description not available]	2.21	1
Anoxemia [description not available]	2.21	1
Complications, Pregnancy [description not available]	2.21	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.21	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.21	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.21	1
Acute Confusional Senile Dementia [description not available]	2.08	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.08	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.08	1
Cancer of Stomach [description not available]	2.11	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.11	1
Benign Neoplasms [description not available]	2.11	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.11	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.13	1
Cerebral Pseudosclerosis [description not available]	2.13	1
Hepatolenticular Degeneration A rare autosomal recessive disease characterized by the deposition of copper in the BRAIN; LIVER; CORNEA; and other organs. It is caused by defects in the ATP7B gene encoding copper-transporting ATPase 2 (EC 3.6.3.4), also known as the Wilson disease protein. The overload of copper inevitably leads to progressive liver and neurological dysfunction such as LIVER CIRRHOSIS; TREMOR; ATAXIA and intellectual deterioration. Hepatic dysfunction may precede neurologic dysfunction by several years.	2.13	1
Chloroma [description not available]	2.13	1
Sarcoma, Myeloid An extramedullary tumor of immature MYELOID CELLS or MYELOBLASTS. Granulocytic sarcoma usually occurs with or follows the onset of ACUTE MYELOID LEUKEMIA.	2.13	1

5-hydroxymethyldeoxycytidine monophosphate

Description

Cross-References

Synonyms (27)

Bioassays (7)

Research

Studies (26)

Market Indicators

Research Demand Index: 12.43

Study Types

5-hydroxymethyldeoxycytidine monophosphate

Description

Cross-References

Synonyms (27)

Bioassays (7)

Research

Studies (26)

Market Indicators

Research Demand Index: 12.43

Study Types

Related Drugs (34)

Related Conditions (35)